Association of Cannabis Use-Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001-2002 and 2012-2013

Overview

Journal Am J Psychiatry

Specialty Psychiatry

Date 2021 Oct 14

PMID 34645275

Citations 14

Authors

Ofir Livne

Dvora Shmulewitz

Aaron L Sarvet

Melanie M Wall

Deborah S Hasin

Affiliations

Soon will be listed here.

Abstract

Objective: The authors sought to determine the association of cannabis indicators with self-reported psychotic disorders in the U.S. general population.

Methods: Participants were from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC; 2001-2002; N=43,093) and NESARC-III (2012-2013; N=36,309). Logistic regression was used to estimate standardized prevalences of past-year self-reported psychotic disorders within each survey and to evaluate the association of past-year self-reported psychotic disorders with indicators of nonmedical cannabis use (any use; frequent use [at least three times/week], daily/near-daily use, and DSM-IV cannabis use disorder) compared with those with no past-year nonmedical cannabis use. Whether the strength of associations differed between surveys was indicated by difference-in-difference tests (between-survey contrasts) and ratios of odds ratios between surveys.

Results: Self-reported psychotic disorders were significantly more prevalent among participants with any nonmedical cannabis use than those without (2001-2002: 1.65% compared with 0.27%; 2012-2013: 1.89% compared with 0.68%). In 2001-2002, self-reported psychotic disorders were unrelated to either frequent use or daily/near-daily use. However, in 2012 - 2013, compared with nonusers, self-reported psychotic disorders were more common among participants with frequent use and those with daily/near-daily nonmedical cannabis use (2012-2013: 2.79% and 2.52%, respectively, compared with 0.68% among nonusers). Self-reported psychotic disorders were significantly more prevalent among participants with cannabis use disorder than nonusers in both surveys (2001-2002: 2.55% compared with 0.27%; 2012 - 2013: 3.38% compared with 0.68%). The strength of these associations did not change over time.

Conclusions: Data from the U.S. general population, especially more recent data, suggest associations between self-reported psychotic disorder and frequent nonmedical cannabis use and cannabis use disorder. Clinicians and policy makers should consider these relationships when monitoring patients and formulating programs.

Citing Articles

Cannabis Use and Cannabis Use Disorder Among U.S. Adults with Psychiatric Disorders: 2001-2002 and 2012-2013.

Hasin D, Mannes Z, Livne O, Fink D, Martins S, Stohl M Subst Use Misuse. 2024; 60(2):285-292.

PMID: 39533528 PMC: 11710973. DOI: 10.1080/10826084.2024.2423374.

Cannabis and Psychosis: Weeding Out Fact from Fiction.

Johnson E, Agrawal A Mo Med. 2024; 121(5):333-339.

PMID: 39421474 PMC: 11482844.

The Role of Cannabis in the Development of Psychosis.

Turkoglu O, Ertugrul A Turk Psikiyatri Derg. 2024; 35(3):234-244.

PMID: 39224996 PMC: 11375744. DOI: 10.5080/u27122.

Unhealthy behaviors associated with mental health disorders: a systematic comparative review of diet quality, sedentary behavior, and cannabis and tobacco use.

Johnstad P Front Public Health. 2024; 11:1268339.

PMID: 38249418 PMC: 10797041. DOI: 10.3389/fpubh.2023.1268339.

Trends in Prevalence of Cannabis Use Disorder Among U.S. Veterans With and Without Psychiatric Disorders Between 2005 and 2019.

Livne O, Malte C, Olfson M, Wall M, Keyes K, Maynard C Am J Psychiatry. 2023; 181(2):144-152.

PMID: 38018141 PMC: 10843609. DOI: 10.1176/appi.ajp.20230168.

References

Chandra S, Radwan M, Majumdar C, Church J, Freeman T, ElSohly M . New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci. 2019; 269(1):5-15. DOI: 10.1007/s00406-019-00983-5. View

Carliner H, Mauro P, Brown Q, Shmulewitz D, Rahim-Juwel R, Sarvet A . The widening gender gap in marijuana use prevalence in the U.S. during a period of economic change, 2002-2014. Drug Alcohol Depend. 2016; 170:51-58. PMC: 5321672. DOI: 10.1016/j.drugalcdep.2016.10.042. View

Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M . Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015; 2(3):233-8. DOI: 10.1016/S2215-0366(14)00117-5. View

Bonn-Miller M, Harris A, Trafton J . Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychol Serv. 2012; 9(4):404-416. DOI: 10.1037/a0027622. View

Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G . Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002; 325(7374):1199. PMC: 135490. DOI: 10.1136/bmj.325.7374.1199. View

Rossler W, Salize H, van Os J, Riecher-Rossler A . Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005; 15(4):399-409. DOI: 10.1016/j.euroneuro.2005.04.009. View

Niv N, Cohen A, Mintz J, Ventura J, Young A . The validity of using patient self-report to assess psychotic symptoms in schizophrenia. Schizophr Res. 2007; 90(1-3):245-50. DOI: 10.1016/j.schres.2006.11.011. View

Knol M, VanderWeele T . Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol. 2012; 41(2):514-20. PMC: 3324457. DOI: 10.1093/ije/dyr218. View

Sideli L, Quigley H, La Cascia C, Murray R . Cannabis Use and the Risk for Psychosis and Affective Disorders. J Dual Diagn. 2019; 16(1):22-42. DOI: 10.1080/15504263.2019.1674991. View

10.

Onwumere J, Bonetto C, Lasalvia A, Miglietta E, Veronese A, Bellini F . Predictors and moderators of burden of care and emotional distress in first-episode psychosis caregivers: results from the GET UP pragmatic cluster randomised controlled trial. Epidemiol Psychiatr Sci. 2019; 29:e27. PMC: 8061200. DOI: 10.1017/S2045796019000155. View

11.

Chang W, Wong C, Chen E, Lam L, Chan W, Ng R . Lifetime Prevalence and Correlates of Schizophrenia-Spectrum, Affective, and Other Non-affective Psychotic Disorders in the Chinese Adult Population. Schizophr Bull. 2017; 43(6):1280-1290. PMC: 5737409. DOI: 10.1093/schbul/sbx056. View

12.

Santaella-Tenorio J, Levy N, Segura L, Mauro P, Martins S . Cannabis use disorder among people using cannabis daily/almost daily in the United States, 2002-2016. Drug Alcohol Depend. 2019; 205:107621. PMC: 7359630. DOI: 10.1016/j.drugalcdep.2019.107621. View

13.

Sharifi V, Eaton W, Wu L, Roth K, Burchett B, Mojtabai R . Psychotic experiences and risk of death in the general population: 24-27 year follow-up of the Epidemiologic Catchment Area study. Br J Psychiatry. 2015; 207(1):30-6. PMC: 4486819. DOI: 10.1192/bjp.bp.113.143198. View

14.

Di Forti M, Morgan C, Selten J, Lynskey M, Murray R . High-potency cannabis and incident psychosis: correcting the causal assumption - Authors' reply. Lancet Psychiatry. 2019; 6(6):466-467. DOI: 10.1016/S2215-0366(19)30176-2. View

15.

. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995):743-800. PMC: 4561509. DOI: 10.1016/S0140-6736(15)60692-4. View

16.

Fusar-Poli P, Salazar de Pablo G, Correll C, Meyer-Lindenberg A, Millan M, Borgwardt S . Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. JAMA Psychiatry. 2020; 77(7):755-765. DOI: 10.1001/jamapsychiatry.2019.4779. View

17.

Semple D, McIntosh A, Lawrie S . Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005; 19(2):187-94. DOI: 10.1177/0269881105049040. View

18.

van Os J, Bak M, Hanssen M, Bijl R, de Graaf R, Verdoux H . Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002; 156(4):319-27. DOI: 10.1093/aje/kwf043. View

19.

Marconi A, Di Forti M, Lewis C, Murray R, Vassos E . Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016; 42(5):1262-9. PMC: 4988731. DOI: 10.1093/schbul/sbw003. View

20.

Murrie B, Lappin J, Large M, Sara G . Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2019; 46(3):505-516. PMC: 7147575. DOI: 10.1093/schbul/sbz102. View